The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of continuous versus intermittent S-1 plus oxaliplatin in first-line treatment of patients with metastatic gastric carcinoma.
Sook Ryun Park
No relevant relationships to disclose
Young-Iee Park
No relevant relationships to disclose
Jiyoung Rhee
No relevant relationships to disclose
Byung-Ho Nam
No relevant relationships to disclose
Sun-Young Kong
No relevant relationships to disclose
Sung Hyun Kim
No relevant relationships to disclose
Mihee Choi
No relevant relationships to disclose
Il Ju Choi
No relevant relationships to disclose
Chan Gyoo Kim
No relevant relationships to disclose
Jong Yeul Lee
No relevant relationships to disclose
Soo-Jeong Cho
No relevant relationships to disclose
Young Woo Kim
No relevant relationships to disclose
Keun Won Ryu
No relevant relationships to disclose
Jun Ho Lee
No relevant relationships to disclose
Noe Kyeong Kim
No relevant relationships to disclose